A Multicenter, Double- Blind, Placebo- Controlled Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera (Dimethyl Fumarate) Delayed Release Capsules

Trial Profile

A Multicenter, Double- Blind, Placebo- Controlled Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera (Dimethyl Fumarate) Delayed Release Capsules

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 May 2017

At a glance

  • Drugs Dimethyl fumarate (Primary) ; Montelukast
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms MITIGATE
  • Sponsors Biogen
  • Most Recent Events

    • 01 May 2017 Planned End Date changed from 1 Jun 2017 to 15 May 2017.
    • 06 Mar 2017 Planned number of patients changed from 295 to 60.
    • 06 Mar 2017 Planned End Date changed from 1 May 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top